Allergic Rhinitis Market to Exhibit Moderate Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Regeneron, Immunotek, Siolta Therapeutics, ASIT Biotech, ILTOO, Emergo, Advagene, AOBiome, Inimmune, Allergy Therapeutics

Allergic Rhinitis Market size in the 7MM is approximately USD 10,175 million in 2022 and is projected to increase during the forecast period (2023-2032). As per DelveInsight, the Allergic Rhinitis Market is anticipated to evolve immensely in the coming years owing to the increasing prevalence of the disease and the launch of the emerging drug. Some of the key products that are likely to hit the market during our study period 2019-2032 include Grass MATA MPL and REGN5713-5714-5715.

DelveInsight's "Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Allergic Rhinitis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Allergic Rhinitis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Allergic Rhinitis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Allergic Rhinitis: An Overview
Allergic rhinitis is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever.

There are two general types of allergic rhinitis, which include seasonal and perennial allergic rhinitis. Seasonal allergies, usually due to cyclic airborne plant pollens, are more common and cause problems to individuals at certain times of the year. Conversely, perennial allergies cause symptoms continuously throughout the year due to constant allergen exposure such as house dust mites, mold spores, cockroaches, cigarette smoke, and pet dander.

Allergic rhinitis can last several weeks, longer than a cold or the flu. It does not cause fever, and the nasal discharge from hay fever is thin, watery, and clear, whereas nasal discharge from a cold or the flu tends to be thicker. Itching (mostly in the eyes, nose, mouth, throat, and skin) is common with allergic rhinitis but not with a cold or the flu. Sneezing occurs more with allergic rhinitis, and patients may even have severe sneeze attacks

Therapeutic options available to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. Other therapies that may be useful in select patients include decongestants and oral corticosteroids. If the patient's symptoms persist despite appropriate treatment, referral to an allergist should be considered.

Therapies that have been approved in the 7MM, including XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer's ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals' (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.(Japan)

Allergic Rhinitis Market Key Facts
• The market size in the 7MM will increase at a CAGR of about 2.2% due to the increasing prevalence of the disease and the launch of the emerging drug
• Among EU countries, Germany and France accounts for the maximum market size of USD 1,337 and USD 977 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 593 million.
• Japan accounts for a market size of USD 2,284 million in 2022, but these dynamics are expected to change in the forecasted years.
• There were 178 million prevalent cases of Allergic Rhinitis estimated to have occurred in the 7MM in 2022 of which 47 million of the cases were estimated to be from the US alone and these cases are anticipated to increase during the forecasted period.
• There were 89 million diagnosed prevalent cases of Allergic Rhinitis estimated to have occurred in the 7MM in 2022 of which 25 million of the accounted cases were estimated to be from the US alone and these cases are anticipated to grow in the foreseeable future during the study period.
• The diagnosed prevalent cases were further divided into severity-specific cases. The severity-specific diagnosed prevalent cases of Allergic Rhinitis are further categorized into mild, moderate, and severe with 17 million, 51 million, and 20 million cases respectively in the 7MM in 2022 which will further increase in the future.

Discover How Allergic Rhinitis Market Will Grow by 2032:
https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Allergic Rhinitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Allergic Rhinitis therapies in the market. It also provides a detailed assessment of the Allergic Rhinitis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Allergic Rhinitis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Allergic Rhinitis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Allergic Rhinitis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Allergic Rhinitis Epidemiology Segmented as -
• Total prevalent cases of Allergic Rhinitis in the 7MM (2019 to 2032)
• Total diagnosed prevalent cases of Allergic Rhinitis in the 7MM (2019 to 2032)
• Age-specific diagnosed prevalent cases of Allergic Rhinitis in the 7MM (2019 to 2032)
• Severity-specific diagnosed prevalent cases of Allergic Rhinitis in the 7MM (2019 to 2032)
• Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in the 7MM (2019 to 2032)

Get Key Insights Into the Evolving Allergic Rhinitis Epidemiology Trends @
https://www.delveinsight.com/report-store/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Allergic Rhinitis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Allergic Rhinitis market or expected to be launched during the study period. The analysis covers the market share by Allergic Rhinitis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Allergic Rhinitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Allergic Rhinitis Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Allergic Rhinitis. Currently, Regeneron Pharmaceuticals is leading the therapeutics market with its Allergic Rhinitis drug candidates in the mid to advanced stage of clinical development.

Leading Companies in the Allergic Rhinitis Therapeutics Market Include
• Abdi Ibrahim Pharmaceuticals
• Regeneron Pharmaceuticals
• Hanmi Pharmaceutical
• Immunotek
• Anhui Palo Alto Pharmaceuticals, Inc.
• Revolo Biotherapeutics
• Emergo Therapeutics, Inc.
• Advagene Biopharma
• AOBiome LLC
• H. Lundbeck A/S
• CSPC ZhongQi Pharmaceutical
• Inimmune
• Allergy Therapeutics
• Array Biopharma
• Siolta Therapeutics
• ASIT biotech
• HAL Allergy Group
• Worg Pharmaceuticals
• ILTOO Pharma
And Many Others

Emerging and Marketed Allergic Rhinitis Therapies Covered in the Report Include
• REGN5713-5714-5715: Regeneron Pharmaceuticals
• MM09-MG01: Immunotek
And Many More

Learn More About the Emerging Therapies & Key Companies in the Allergic Rhinitis Therapeutics Market:
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Allergic Rhinitis Competitive Intelligence Analysis
4. Allergic Rhinitis Market Overview at a Glance
5. Allergic Rhinitis Background and Overview
6. Allergic Rhinitis Patient Journey
7. Allergic Rhinitis Epidemiology and Patient Population
8. Allergic Rhinitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Allergic Rhinitis Unmet Needs
10. Key Endpoints of Allergic Rhinitis Treatment
11. Allergic Rhinitis Marketed Products
12. Allergic Rhinitis Emerging Therapies
13. Allergic Rhinitis Seven Major Market Analysis
14. Attribute Analysis
15. Allergic Rhinitis Market Outlook (7 major markets)
16. Allergic Rhinitis Access and Reimbursement Overview
17. KOL Views on the Allergic Rhinitis Market.
18. Allergic Rhinitis Market Drivers
19. Allergic Rhinitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/allergic-rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market

Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Panuveitis Market
https://www.delveinsight.com/report-store/panuveitis-market

Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market

mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market

Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market

Audiology Devices Market
https://www.delveinsight.com/report-store/audiology-devices-market

Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market

Cancer Vaccines Market
https://www.delveinsight.com/report-store/cancer-vaccines-market

CAR-T Pipeline Insight
https://www.delveinsight.com/report-store/car-t-pipeline-insight

Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Physiotherapy Equipment Market
https://www.delveinsight.com/report-store/physiotherapy-equipment-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Migraine Market
https://www.delveinsight.com/report-store/migraine-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Renal Vasculitis Market
https://www.delveinsight.com/report-store/renal-vasculitis-market

Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market

Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Lipodystrophy Market
https://www.delveinsight.com/report-store/lipodystrophy-market

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.